Request Sample Inquiry
Liquid Biopsy Market

Liquid Biopsy Market

Liquid Biopsy Market - Global Industry Assessment & Forecast

img
Biotechnology and Life Sciences
Number Of Pages # Pages:

142

Base Year:

2023

Date

Jul - 2024

Format:

PDF XLS PPT

Report Code:

VMR-2009

Segments Covered
  • By Product & Services By Product & Services Assay Kits, Instruments, Services
  • By Circulating Biomarkers By Circulating Biomarkers Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Circulating Tumor DNA (ctDNA) , Cell-free DNA (cfDNA), Extracellular Vesicles (EVS), Other Circulating Biomarkers
  • By Clinical Applications By Clinical Applications Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring
  • By Technology By Technology Multi-Gene Parallel Analysis using NGS, Single-Gene Analysis using PCR Microarrays
  • By Application By Application Cancer Applications, Non-Cancer Applications
  • By Sample Type By Sample Type Blood, Other Sample Types
  • By End User By End User Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers, Other End Users
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 5.64 Billion
Revenue 2032Revenue 2032: USD 15.75 Billion
Revenue CAGRRevenue CAGR (2024 - 2032): 12.09%
Fastest Growing Region Fastest Growing Region (2024 - 2032) Asia Pacific
Largest Region Largest Region (2023): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Liquid Biopsy Market - Segment Analysis
    1. Overview
    2. Global Liquid Biopsy Market, 2016 - 2028 (USD Million)
    3. Global Liquid Biopsy Market - by Product & Services
      1. By Assay Kits
      2. By Instruments
      3. By Services
    4. Global Liquid Biopsy Market - by Circulating Biomarkers
      1. By Circulating Tumor Cells
      2. By Circulating Tumor DNA (ctDNA)
      3. By Circulating Tumor DNA (ctDNA)
      4. By Cell-free DNA (cfDNA)
      5. By Extracellular Vesicles (EVS)
      6. By Other Circulating Biomarkers
    5. Global Liquid Biopsy Market - by Clinical Applications
      1. By Early Cancer Screening
      2. By Therapy Selection
      3. By Treatment Monitoring
      4. By Recurrence Monitoring
    6. Global Liquid Biopsy Market - by Technology
      1. By Multi-Gene Parallel Analysis using NGS
      2. By Single-Gene Analysis using PCR Microarrays
    7. Global Liquid Biopsy Market - by Application
      1. By Cancer Applications
      2. By Non-Cancer Applications
    8. Global Liquid Biopsy Market - by Sample Type
      1. By Blood
      2. By Other Sample Types
    9. Global Liquid Biopsy Market - by End User
      1. By Reference Laboratories
      2. By Hospitals & Physician Laboratories
      3. By Academic & Research Centers
      4. By Other End Users
    10. Global Liquid Biopsy Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    11. Market comparative analysis
  4. North America Liquid Biopsy Market - Segment Analysis
    1. Overview
    2. North America Liquid Biopsy Market, 2016 - 2028 (USD Million)
    3. North America Liquid Biopsy Market, by Product & Services
      1. By Assay Kits
      2. By Instruments
      3. By Services
    4. North America Liquid Biopsy Market, by Circulating Biomarkers
      1. By Circulating Tumor Cells
      2. By Circulating Tumor DNA (ctDNA)
      3. By Circulating Tumor DNA (ctDNA)
      4. By Cell-free DNA (cfDNA)
      5. By Extracellular Vesicles (EVS)
      6. By Other Circulating Biomarkers
    5. North America Liquid Biopsy Market, by Clinical Applications
      1. By Early Cancer Screening
      2. By Therapy Selection
      3. By Treatment Monitoring
      4. By Recurrence Monitoring
    6. North America Liquid Biopsy Market, by Technology
      1. By Multi-Gene Parallel Analysis using NGS
      2. By Single-Gene Analysis using PCR Microarrays
    7. North America Liquid Biopsy Market, by Application
      1. By Cancer Applications
      2. By Non-Cancer Applications
    8. North America Liquid Biopsy Market, by Sample Type
      1. By Blood
      2. By Other Sample Types
    9. North America Liquid Biopsy Market, by End User
      1. By Reference Laboratories
      2. By Hospitals & Physician Laboratories
      3. By Academic & Research Centers
      4. By Other End Users
    10. North America Liquid Biopsy Market, by Country
      1. U.S.
        1. U.S. Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. U.S. Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. U.S. Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. U.S. Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. U.S. Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. U.S. Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. U.S. Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      2. Canada
        1. Canada Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Canada Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Canada Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Canada Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Canada Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Canada Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Canada Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      3. Mexico
        1. Mexico Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Mexico Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Mexico Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Mexico Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Mexico Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Mexico Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Mexico Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
  5. Europe Liquid Biopsy Market - Segment Analysis
    1. Overview
    2. Europe Liquid Biopsy Market, 2016 - 2028 (USD Million)
    3. Europe Liquid Biopsy Market, by Product & Services
      1. By Assay Kits
      2. By Instruments
      3. By Services
    4. Europe Liquid Biopsy Market, by Circulating Biomarkers
      1. By Circulating Tumor Cells
      2. By Circulating Tumor DNA (ctDNA)
      3. By Circulating Tumor DNA (ctDNA)
      4. By Cell-free DNA (cfDNA)
      5. By Extracellular Vesicles (EVS)
      6. By Other Circulating Biomarkers
    5. Europe Liquid Biopsy Market, by Clinical Applications
      1. By Early Cancer Screening
      2. By Therapy Selection
      3. By Treatment Monitoring
      4. By Recurrence Monitoring
    6. Europe Liquid Biopsy Market, by Technology
      1. By Multi-Gene Parallel Analysis using NGS
      2. By Single-Gene Analysis using PCR Microarrays
    7. Europe Liquid Biopsy Market, by Application
      1. By Cancer Applications
      2. By Non-Cancer Applications
    8. Europe Liquid Biopsy Market, by Sample Type
      1. By Blood
      2. By Other Sample Types
    9. Europe Liquid Biopsy Market, by End User
      1. By Reference Laboratories
      2. By Hospitals & Physician Laboratories
      3. By Academic & Research Centers
      4. By Other End Users
    10. Europe Liquid Biopsy Market, by Country
      1. Germany
        1. Germany Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Germany Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Germany Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Germany Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Germany Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Germany Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Germany Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      2. UK
        1. UK Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. UK Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. UK Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. UK Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. UK Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. UK Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. UK Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      3. France
        1. France Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. France Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. France Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. France Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. France Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. France Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. France Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      4. Spain
        1. Spain Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Spain Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Spain Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Spain Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Spain Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Spain Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Spain Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      5. Italy
        1. Italy Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Italy Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Italy Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Italy Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Italy Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Italy Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Italy Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      6. BENELUX
        1. BENELUX Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. BENELUX Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. BENELUX Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. BENELUX Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. BENELUX Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. BENELUX Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. BENELUX Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      7. Rest of Europe
        1. Rest Of Europe Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Rest Of Europe Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Rest Of Europe Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Rest Of Europe Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Rest Of Europe Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Rest Of Europe Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Rest Of Europe Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
  6. Asia Pacific Liquid Biopsy Market - Segment Analysis
    1. Overview
    2. Asia Pacific Liquid Biopsy Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Liquid Biopsy Market, by Product & Services
      1. By Assay Kits
      2. By Instruments
      3. By Services
    4. Asia Pacific Liquid Biopsy Market, by Circulating Biomarkers
      1. By Circulating Tumor Cells
      2. By Circulating Tumor DNA (ctDNA)
      3. By Circulating Tumor DNA (ctDNA)
      4. By Cell-free DNA (cfDNA)
      5. By Extracellular Vesicles (EVS)
      6. By Other Circulating Biomarkers
    5. Asia Pacific Liquid Biopsy Market, by Clinical Applications
      1. By Early Cancer Screening
      2. By Therapy Selection
      3. By Treatment Monitoring
      4. By Recurrence Monitoring
    6. Asia Pacific Liquid Biopsy Market, by Technology
      1. By Multi-Gene Parallel Analysis using NGS
      2. By Single-Gene Analysis using PCR Microarrays
    7. Asia Pacific Liquid Biopsy Market, by Application
      1. By Cancer Applications
      2. By Non-Cancer Applications
    8. Asia Pacific Liquid Biopsy Market, by Sample Type
      1. By Blood
      2. By Other Sample Types
    9. Asia Pacific Liquid Biopsy Market, by End User
      1. By Reference Laboratories
      2. By Hospitals & Physician Laboratories
      3. By Academic & Research Centers
      4. By Other End Users
    10. Asia Pacific Liquid Biopsy Market, by Country
      1. China
        1. China Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. China Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. China Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. China Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. China Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. China Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. China Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      2. Japan
        1. Japan Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Japan Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Japan Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Japan Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Japan Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Japan Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Japan Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      3. India
        1. India Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. India Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. India Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. India Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. India Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. India Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. India Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      4. South Korea
        1. South Korea Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. South Korea Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. South Korea Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. South Korea Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. South Korea Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. South Korea Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. South Korea Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      5. South East Asia
        1. South East Asia Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. South East Asia Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. South East Asia Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. South East Asia Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. South East Asia Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. South East Asia Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. South East Asia Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Rest of Asia Pacific Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Rest of Asia Pacific Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Rest of Asia Pacific Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Rest of Asia Pacific Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Rest of Asia Pacific Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Rest of Asia Pacific Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
  7. Latin America Liquid Biopsy Market - Segment Analysis
    1. Overview
    2. Latin America Liquid Biopsy Market, 2016 - 2028 (USD Million)
    3. Latin America Liquid Biopsy Market, by Product & Services
      1. By Assay Kits
      2. By Instruments
      3. By Services
    4. Latin America Liquid Biopsy Market, by Circulating Biomarkers
      1. By Circulating Tumor Cells
      2. By Circulating Tumor DNA (ctDNA)
      3. By Circulating Tumor DNA (ctDNA)
      4. By Cell-free DNA (cfDNA)
      5. By Extracellular Vesicles (EVS)
      6. By Other Circulating Biomarkers
    5. Latin America Liquid Biopsy Market, by Clinical Applications
      1. By Early Cancer Screening
      2. By Therapy Selection
      3. By Treatment Monitoring
      4. By Recurrence Monitoring
    6. Latin America Liquid Biopsy Market, by Technology
      1. By Multi-Gene Parallel Analysis using NGS
      2. By Single-Gene Analysis using PCR Microarrays
    7. Latin America Liquid Biopsy Market, by Application
      1. By Cancer Applications
      2. By Non-Cancer Applications
    8. Latin America Liquid Biopsy Market, by Sample Type
      1. By Blood
      2. By Other Sample Types
    9. Latin America Liquid Biopsy Market, by End User
      1. By Reference Laboratories
      2. By Hospitals & Physician Laboratories
      3. By Academic & Research Centers
      4. By Other End Users
    10. Latin America Liquid Biopsy Market, by Country
      1. Brazil
        1. Brazil Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Brazil Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Brazil Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Brazil Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Brazil Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Brazil Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Brazil Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      2. Argentina
        1. Argentina Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Argentina Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Argentina Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Argentina Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Argentina Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Argentina Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Argentina Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      3. Rest of Latin America
        1. Rest of Latin America Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Rest of Latin America Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Rest of Latin America Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Rest of Latin America Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Rest of Latin America Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Rest of Latin America Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Rest of Latin America Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
  8. Middle East & Africa Liquid Biopsy Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Liquid Biopsy Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Liquid Biopsy Market, by Product & Services
      1. By Assay Kits
      2. By Instruments
      3. By Services
    4. Middle East & Africa Liquid Biopsy Market, by Circulating Biomarkers
      1. By Circulating Tumor Cells
      2. By Circulating Tumor DNA (ctDNA)
      3. By Circulating Tumor DNA (ctDNA)
      4. By Cell-free DNA (cfDNA)
      5. By Extracellular Vesicles (EVS)
      6. By Other Circulating Biomarkers
    5. Middle East & Africa Liquid Biopsy Market, by Clinical Applications
      1. By Early Cancer Screening
      2. By Therapy Selection
      3. By Treatment Monitoring
      4. By Recurrence Monitoring
    6. Middle East & Africa Liquid Biopsy Market, by Technology
      1. By Multi-Gene Parallel Analysis using NGS
      2. By Single-Gene Analysis using PCR Microarrays
    7. Middle East & Africa Liquid Biopsy Market, by Application
      1. By Cancer Applications
      2. By Non-Cancer Applications
    8. Middle East & Africa Liquid Biopsy Market, by Sample Type
      1. By Blood
      2. By Other Sample Types
    9. Middle East & Africa Liquid Biopsy Market, by End User
      1. By Reference Laboratories
      2. By Hospitals & Physician Laboratories
      3. By Academic & Research Centers
      4. By Other End Users
    10. Middle East & Africa Liquid Biopsy Market, by Country
      1. GCC Countries
        1. GCC Countries Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. GCC Countries Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. GCC Countries Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. GCC Countries Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. GCC Countries Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. GCC Countries Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. GCC Countries Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      2. South Africa
        1. South Africa Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. South Africa Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. South Africa Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. South Africa Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. South Africa Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. South Africa Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. South Africa Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Liquid Biopsy Market, By Product & Services
          1. By Assay Kits
          2. By Instruments
          3. By Services
        2. Rest of Middle East & Africa Liquid Biopsy Market, By Circulating Biomarkers
          1. By Circulating Tumor Cells
          2. By Circulating Tumor DNA (ctDNA)
          3. By Circulating Tumor DNA (ctDNA)
          4. By Cell-free DNA (cfDNA)
          5. By Extracellular Vesicles (EVS)
          6. By Other Circulating Biomarkers
        3. Rest of Middle East & Africa Liquid Biopsy Market, By Clinical Applications
          1. By Early Cancer Screening
          2. By Therapy Selection
          3. By Treatment Monitoring
          4. By Recurrence Monitoring
        4. Rest of Middle East & Africa Liquid Biopsy Market, By Technology
          1. By Multi-Gene Parallel Analysis using NGS
          2. By Single-Gene Analysis using PCR Microarrays
        5. Rest of Middle East & Africa Liquid Biopsy Market, By Application
          1. By Cancer Applications
          2. By Non-Cancer Applications
        6. Rest of Middle East & Africa Liquid Biopsy Market, By Sample Type
          1. By Blood
          2. By Other Sample Types
        7. Rest of Middle East & Africa Liquid Biopsy Market, By End User
          1. By Reference Laboratories
          2. By Hospitals & Physician Laboratories
          3. By Academic & Research Centers
          4. By Other End Users
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Bio-Rad Laboratories
    2. Biocept Inc.
    3. Guardant Health
    4. Illumina Inc.
    5. F. Hoffmann-La Roche Ltd.
    6. Johnson & Johnson
    7. Laboratory Corporation of America Holdings
    8. MDxHealth SA
    9. QIAGEN N.V.
    10. Thermo Fisher Scientific Inc.
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
Vantage Market Research | 13-Feb-2023
Liquid Biopsy Market to Reach Valuation of USD 10.9 Billion by 2028 – Growing Influence and Prevalence of Cancer Drives the Market
FAQ
Frequently Asked Question

  • The global Liquid Biopsy valued at USD 5.64 Billion in 2023 and is expected to reach USD 15.75 Billion in 2032 growing at a CAGR of 12.09%.

  • The prominent players in the market are Bio-Rad Laboratories, Biocept Inc., Guardant Health, Illumina Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Laboratory Corporation of America Holdings, MDxHealth SA, QIAGEN N.V., Thermo Fisher Scientific Inc..

  • The market is project to grow at a CAGR of 12.09% between 2024 and 2032.

  • The driving factors of the Liquid Biopsy include

    • Liquid biopsy offers many advantages over traditional tissue biopsy methods, driving its adoption in clinical practice

  • North America was the leading regional segment of the Liquid Biopsy in 2023.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy